Compare ARK Genomic Revolution ETF (ARKG) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Shell PLC — how do they compare? ARK Genomic Revolution ETF trades at $44.58, while Shell PLC trades at $90.08 (market cap $250.44B). The key difference: Shell PLC pays a 3.45% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Shell PLC nearer its low. Which is the better fit depends on your goals.
| ARKG | SHEL | |
|---|---|---|
Sector | Sector/Thematic | Energy |
52-Week High | $44.55 | $94.15 |
52-Week Low | $24.02 | $70.31 |
Market Cap | — | $250.44B |
Enterprise Value | — | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
SHEL trades at $90.12, up 0.19% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beating estimates. The stock shows attractive valuation metrics with a P/E of 10.01 and P/S of 0.88, supported by a 14.35% ROE and 8.76% net income margin. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments, such as selling its European renewables unit to TotalEnergies.
Outlook remains positive due to discounted valuation, rising cash flow, and analyst consensus favoring buys with a $103.60 price target. Key risks include commodity price volatility, regulatory pressures, and execution challenges in energy transitions. The stock offers value with upside potential but requires monitoring of oil market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
